{"ticker": {"uuid": "b5f7b81c-a735-4d6a-b25f-d3a8b355d521", "symbol": "CRBP", "name": "Corbus Pharmaceuticals Holding", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Corbus Pharmaceuticals Holdings Inc. stock rises Tuesday, still underperforms market", "summary": "Corbus Pharmaceuticals Holdings Inc. (CRBP) saw its stock rise by 1.01% on Tuesday, closing at $8.98. Despite this increase, the stock underperformed the broader market, as both the NASDAQ Composite and Dow Jones Industrial Average also climbed. The company's shares remain signif", "url": "https://www.marketwatch.com/data-news/corbus-pharmaceuticals-holdings-inc-stock-rises-tuesday-still-underperforms-market-f4e4aba9-5ba1e4ebaba0", "source_name": "MarketWatch", "published_at": "2026-07-21T17:19:00", "published_display": "21 Jul 2026 17:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day", "summary": "Corbus Pharmaceuticals Holdings Inc. (CRBP) saw its stock rise by 2.39% to $9.01 on Friday, despite a generally poor trading session for the broader market where both the NASDAQ Composite and Dow Jones Industrial Average declined. This increase broke a four-day losing streak for ", "url": "https://www.marketwatch.com/data-news/corbus-pharmaceuticals-holdings-inc-stock-outperforms-competitors-on-strong-trading-day-36aa5d5f-4b50e581e36d?mod=mw_quote_news", "source_name": "MarketWatch", "published_at": "2026-07-17T17:20:00", "published_display": "17 Jul 2026 17:20", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day", "summary": "Corbus Pharmaceuticals Holdings Inc. (CRBP) saw its stock price decline by 2.33% to $8.80, marking its fourth consecutive day of losses. This occurred during a general market downturn, with both the NASDAQ Composite and Dow Jones Industrial Average also falling. Despite the daily", "url": "https://www.marketwatch.com/data-news/corbus-pharmaceuticals-holdings-inc-stock-outperforms-competitors-despite-losses-on-the-day-41ad6dc9-a0d0144f05cd?mod=goog_fin_scmw", "source_name": "MarketWatch", "published_at": "2026-07-16T17:19:00", "published_display": "16 Jul 2026 17:19", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors", "summary": "Shares of Corbus Pharmaceuticals Holdings Inc. (CRBP) fell 6.61% to $9.04 on Monday, breaking a four-day winning streak. This underperformance occurred during an overall poor trading session, with the NASDAQ Composite Index falling 1.55% and the Dow Jones Industrial Average decli", "url": "https://www.marketwatch.com/data-news/corbus-pharmaceuticals-holdings-inc-stock-underperforms-monday-when-compared-to-competitors-31c79946-c684017a7ce7?mod=mw_quote_news", "source_name": "MarketWatch", "published_at": "2026-07-13T17:21:00", "published_display": "13 Jul 2026 17:21", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enterprise value to EBIT forward of Corbus Pharmaceuticals Holdings, Inc. \u2013 NASDAQ:CRBP", "summary": "This article provides financial information for Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) from TradingView, specifically focusing on its enterprise value to EBIT forward. The content appears to be a financial data page rather than a traditional article, offering variou", "url": "https://www.tradingview.com/symbols/NASDAQ-CRBP/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T12:39:18", "published_display": "12 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer", "summary": "Corbus Pharmaceuticals Holdings, Inc. has announced the appointment of Leonardo Viana Nicacio, M.D., as its new Chief Medical Officer. Dr. Nicacio brings extensive experience in solid tumor drug development, particularly with antibody-drug conjugates (ADCs) and HPV-driven oncolog", "url": "https://www.theglobeandmail.com/investing/markets/stocks/CRBP-Q/pressreleases/36762811/corbus-pharmaceuticals-appoints-leonardo-viana-nicacio-m-d-as-chief-medical-officer/", "source_name": "The Globe and Mail", "published_at": "2026-07-11T04:11:21", "published_display": "11 Jul 2026 04:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Holdings Inc. stock rises Thursday, still underperforms market", "summary": "Corbus Pharmaceuticals Holdings Inc. (CRBP) stock increased by 1.15% on Thursday, closing at $9.66", "url": "https://www.marketwatch.com/data-news/corbus-pharmaceuticals-holdings-inc-stock-rises-thursday-still-underperforms-market-c8094119-b093795a5eb2", "source_name": "MarketWatch", "published_at": "2026-07-09T17:18:00", "published_display": "09 Jul 2026 17:18", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains", "summary": "Corbus Pharmaceuticals Holdings Inc. (CRBP) saw its stock increase by 1.81% on Wednesday, closing at $9.55, despite the broader market showing mixed results. The NASDAQ Composite Index rose while the Dow Jones Industrial Average fell. This marks the second consecutive day of gain", "url": "https://www.marketwatch.com/data-news/corbus-pharmaceuticals-holdings-inc-stock-underperforms-wednesday-when-compared-to-competitors-despite-daily-gains-bf0e718f-cdd3a285e37e", "source_name": "MarketWatch", "published_at": "2026-07-08T17:17:00", "published_display": "08 Jul 2026 17:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio as Chief Medical Officer", "summary": "Corbus Pharmaceuticals has appointed Leonardo Viana Nicacio, M.D., as Chief Medical Officer, strengthening its oncology drug development team. This appointment comes as Corbus prepares to advance multiple oncology and obesity programs, including the registrational TEMPO-1 study f", "url": "https://www.citybiz.co/article/870216/corbus-pharmaceuticals-appoints-leonardo-viana-nicacio-as-chief-medical-officer/", "source_name": "citybiz", "published_at": "2026-07-06T17:40:32", "published_display": "06 Jul 2026 17:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Holdings, Inc. Announces Appointment of Leonardo Viana Nicacio as Chief Medical Officer", "summary": "Corbus Pharmaceuticals Holdings, Inc. has announced the appointment of Leonardo Viana Nicacio, M.D., as its new Chief Medical Officer. Dr. Nicacio brings over 20 years of experience in the pharmaceutical industry, having previously served as Chief Medical Officer at Protara Thera", "url": "https://www.marketscreener.com/news/corbus-pharmaceuticals-holdings-inc-announces-appointment-of-leonardo-viana-nicacio-as-chief-medic-ce7f5edbdb8cf02d", "source_name": "www.marketscreener.com", "published_at": "2026-07-06T15:40:32", "published_display": "06 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer", "summary": "Corbus Pharmaceuticals has announced the appointment of Leonardo Viana Nicacio, M.D., as its new Chief Medical Officer, effective immediately. Dr. Nicacio brings extensive experience in drug development across various therapeutic areas, including oncology and rare diseases, which", "url": "https://www.moomoo.com/news/post/72522140/press-release-corbus-pharmaceuticals-appoints-leonardo-viana-nicacio-md-as", "source_name": "Moomoo", "published_at": "2026-07-06T12:42:07", "published_display": "06 Jul 2026 12:42", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals names Leonardo Nicacio as CMO By Investing.com", "summary": "Corbus Pharmaceuticals Holdings, Inc. announced the appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer, bringing over 20 years of pharmaceutical industry experience to the company. Dr. Nicacio previously held significant roles at Protara Therapeutics, Seagen, A", "url": "https://ca.investing.com/news/stock-market-news/corbus-pharmaceuticals-names-leonardo-nicacio-as-cmo-93CH-4720854", "source_name": "Investing.com Canada", "published_at": "2026-07-06T12:25:35", "published_display": "06 Jul 2026 12:25", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals (NASDAQ: CRBP) hires new CMO and details CRB-701, CRB-913 timelines", "summary": "Corbus Pharmaceuticals has appointed Leonardo Viana Nicacio, M.D., as its new Chief Medical Officer, effective August 3, 2026, with a compensation package including a $545,000 base salary and $2.1 million in equity awards. The company also outlined key clinical development milest", "url": "https://www.stocktitan.net/sec-filings/CRBP/8-k-corbus-pharmaceuticals-holdings-inc-reports-material-event-ccc2dd374f59.html", "source_name": "Stock Titan", "published_at": "2026-07-06T12:16:35", "published_display": "06 Jul 2026 12:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus adds new medical chief ahead of CRB-701 cancer study", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQdzZIblRkYVliU0F5MFdZVEhiRGlQN0R5aWhicVFJVXZuVnVqaW5fbF9WcFd3b0xha2k5U3h4eTBEdG50bXQxSjBTYjBqdDdxOEZCUkZBM0JBbFNFckhFX1F3cElYZzVwZ2lXRGtpbUVJTFlIcmRnRWtIX2g3S19fMDQ3TEJ3cGl0OFdqYk9heEMwNmN0N1FfOEFCMEt6QTZvWEd5Ym9tUGVWVzNzeHQ3dU5GRGw1d3lrNkhjallkQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals outlines its immuno-oncology strategy as a clinical-stage biotech", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPQlBqdTRwZExCamZWQ0NJNVhXVnN2NWs1dEVMd2ZvUTdFOVQyWTlrN1BGSFhsb0szUGVpRTB4VkVGV1I3Y1dIU3RCSVhtaVFHRTllLWZGX093MV9kQks5b1h6SGhYcTB5UF9EVnlGRjU5YTByU2t0aDRVRno5Z2ZoLWtXSDVtVW40UlhiUVFiX3dzbU0tM0pORmo4TjJuQkhqaXVWWWlaaDNDN2ZGSWJiVDkxWWpRcXNVTjZfQlEyWHJxZw?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T13:59:45+00:00", "published_display": "03 Jul 2026 13:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors despite daily gains", "summary": "Corbus Pharmaceuticals Holdings Inc. (CRBP) stock rose 1.98% on Thursday to $9.25, amidst a mixed trading session where the Dow Jones Industrial Average gained 1.14% and the NASDAQ Composite Index fell 0.80%. Despite the daily gains, the stock underperformed compared to some comp", "url": "https://www.marketwatch.com/data-news/corbus-pharmaceuticals-holdings-inc-stock-underperforms-thursday-when-compared-to-competitors-despite-daily-gains-5fdb9891-50af8718823a?mod=mw_quote_news", "source_name": "MarketWatch", "published_at": "2026-07-02T16:17:00", "published_display": "02 Jul 2026 16:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors", "summary": "Shares of Corbus Pharmaceuticals Holdings Inc. (CRBP) fell 3.30% on Wednesday, closing at $9.07. This underperformance occurred during a generally negative trading session, with both the NASDAQ Composite Index and the Dow Jones Industrial Average also declining. The stock's drop ", "url": "https://www.marketwatch.com/data-news/corbus-pharmaceuticals-holdings-inc-stock-underperforms-wednesday-when-compared-to-competitors-c6d2c92b-dbdc105215da?mod=goog_fin_scmw", "source_name": "MarketWatch", "published_at": "2026-07-01T17:19:00", "published_display": "01 Jul 2026 17:19", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(CRBP) Risk Channels and Responsive Allocation", "summary": "This article provides a detailed analysis of Corbus Pharmaceuticals Holdings Inc. (CRBP), highlighting near and mid-term strong sentiment but a weak long-term outlook. It outlines several AI-generated trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging\u2014with s", "url": "https://news.stocktradersdaily.com/news_release/38/CRBP_Risk_Channels_and_Responsive_Allocation_063026042002_1782850802.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-30T16:20:00", "published_display": "30 Jun 2026 16:20", "sentiment": "positive", "sentiment_pct": 63, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell 2000 Value Benchmark", "summary": "Corbus Pharmaceuticals Holdings, Inc. (NasdaqCM: CRBP) has been added to the Russell 2000 Value Benchmark, effective June 29, 2026. This news follows a previous announcement of its inclusion in the Russell 3000E Index. The company is focused on oncology and obesity, with a pipeli", "url": "https://www.marketscreener.com/news/corbus-pharmaceuticals-holdings-inc-nasdaqcm-crbp-added-to-russell-2000-value-benchmark-ce7f5fdfd888f024", "source_name": "marketscreener.com", "published_at": "2026-06-29T14:41:46", "published_display": "29 Jun 2026 14:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Corbus Pharmaceuticals Holdings, Inc. \u2013 BOATS:CRBP", "summary": "This article provides the enterprise value to EBIT forward for Corbus Pharmaceuticals Holdings, Inc. (CRBP) within the Blue Ocean Alternative Trade System (BOATS) on TradingView. It indicates that the market was closed at the time of viewing and presents financial data provided b", "url": "https://www.tradingview.com/symbols/BOATS-CRBP/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T10:39:10", "published_display": "26 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRBP Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast for Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock, including current price, historical performance, analyst price targets, and key financial data. It highlights that analysts have a max estimated price target of $52.00 and a min of $17.00. The", "url": "https://www.tradingview.com/symbols/NASDAQ-CRBP/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T06:10:35", "published_display": "26 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Corbus Pharmaceuticals Holdings, Inc. \u2013 NASDAQ:CRBP", "summary": "This article provides financial information for Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), specifically focusing on its enterprise value to revenue forward. It appears to be a financial data point from TradingView, a platform offering market data and analysis tools.", "url": "https://www.tradingview.com/symbols/NASDAQ-CRBP/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T23:10:35", "published_display": "25 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer Adjusts PT on Corbus Pharmaceuticals to $52 From $54, Maintains Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/oppenheimer-adjusts-pt-corbus-pharmaceuticals-123131238.html", "source_name": "MT Newswires", "published_at": "2026-06-17T12:31:31+00:00", "published_display": "17 Jun 2026 12:31", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near", "summary": "", "url": "https://finance.yahoo.com/m/16c5a21f-3ef1-3c53-827b-64fa4b9b6b57/corbus-pharmaceuticals-teases.html", "source_name": "MarketBeat", "published_at": "2026-06-09T09:02:11+00:00", "published_display": "09 Jun 2026 09:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Spends US$101k Buying More Shares In Corbus Pharmaceuticals Holdings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxNSENWcDdod0xuWHVnSFdGZ1JIamxoOGdyWm5McDFMWUNFX2xfcVJtbTZ3cEVVbDZianhRUXBPUG1NQkRqRl9RekpTaTlMZXZ0VFpBZUdteGdiTnliSlFEMXVFS1JZRTFNSTNPWmUzM0NMV1JuTDVvZy1QTEhfQnpob25oSG1CTE0wejVISjE2YndnWGthcW5TMGxGUlBDX0pmRk43QVFWNmNCbGdfcHV4VWlLX1B4c19HU3VSM2JLcWJ2cnJabjFneFBjQXczQm4xTG5YNVJOM3JxbmluLVljT29tZ1g0cjN5Vl9PX0Y3aEVyUUwzT0ZmQdIB_gFBVV95cUxQUEtaWGlGOVhFbllLd0pwYmVjVThlWEZfNGdjUkxhQTFFUlQ0WXZjY3JtejBPMzlPb0ZnampScm5NUmU3d2dCOE5EckZBcFhEQ2p2NXVWR3Zta3pMUGNNNXFlU2hINEpIVElmdUQ2aTY1d2J1eEM4X1JCN2FxRHhzWFZDOTB3aW9qczNNQnRBQk40bjBoUGp4cjV3Z080TS1RcDdTWFJERHhmLWIwZjhsNkhheVNHalVRT2FuLXVNdnlYUzg1LVdkMjhpd3NnTWpodXFJR0NrVGsyVUpuakpSa09ic2N5dk9RNG5ETXFUSnZNVGtYWnE1bHBjQ0t5dw?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus (CRBP) Chief Business Officer buys 13,500 shares in open market", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNaThmTk80V3kyTkZTUlZaeEFmMWJzMmlLQ3RFTDM4RnhWZmhNdFVETmtub2JFdndyOUllRk9udXFtUmxiNDh1enZDbG1hXzl6LVloWjBvSGdteWJTZDZsSFhZbjJRMzkxLXg0Qm1fUFNZSy13OWxHaURuN2VzTUpHbzM0TUhrTjV5ZHBTN2FaV1BoY3BhXzFCd0JQd1Exc1hfdWJ2bDByWW05U2VWR1NvdlJrSE1jUnRBeFc5OUR0dzZIX0FKc3p1Mg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study", "summary": "", "url": "https://finance.yahoo.com/m/8bb524be-8e00-344d-8d6f-f440cf9360ce/corbus-pharmaceuticals.html", "source_name": "MarketBeat", "published_at": "2026-06-01T14:04:00+00:00", "published_display": "01 Jun 2026 14:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock Price Today: $9.01", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE1DR2VsTzM3bzJhRWNyMXpzaHB5d044eWRCNi1QNDhOSEZUR1N0OGJ3WkhBNDF0THUxTFpWV1NDQlVRaHJhTmVXVTRUTUZzQ01qN0hoWUZ1dw?oc=5", "source_name": "Gotrade", "published_at": "2026-05-29T05:48:29+00:00", "published_display": "29 May 2026 05:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals (CRBP) Is Down 19.6% After FDA Aligns On CRB-701 Registrational Strategy - Has The Bull Case Changed?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals: I'd Preach Caution After Selloff On Latest Data Drop (NASDAQ:CRBP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPYlRqaWRXc0VPblV4NjNxOXdONHhhMGp3eWRLUWxaWGl1OEV1TEVVdGg1VWNralNjeVJBbm9jdlJFYWU0SVJkSU1VU0wxbnkwS2xsTG5nQmxsZVFqR3BpOTJBejZKOFJhaGJYaGd4Qms5ck1pV1FYdjgxaEJTb3pYRHdkWGltZUpnZzUxdmVkcmp6WmdYUDM2UXRlTFBuYkpfZEs0Z1BNNk5TUlZOQ2l3d0V3ZURaQQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/corbus-pharmaceuticals-reports-updated-crb-110000390.html", "source_name": "GlobeNewswire", "published_at": "2026-05-26T11:00:00+00:00", "published_display": "26 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Stock (CRBP) Opinions on Updated CRB-701 Cancer Data Release", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPSE1VMS1uV1NnZldoUG1VbXRRaHpCQ0F3c0dkWF9UTnRkem40LUhoR2lTRFJqV2J3bFZCQ1hISFhCQ016OVBKTktSZE83NVBrMzB6VlNnOXJKbHNiQk0zbDlrZG84NHJGTl9DcmhSemNVa0NKSDE3X0xaMl9ta3BFZEZBQ3FmTHJzWkdXLS1vVXB5SG4tLWxPQ2VaREQ2QU0wSUJaakc1MFFqOERZb2RtaGV2N19XS0VweFpucA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharma (CRBP) Faces Premarket Decline Following Phase 1/2 Trial Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPU28zVTcwN0FrRzZobFpjWUp5ZG01d192R1FSVTB3eEE3UXFxc3FTNUw0SnVMb2Q1a1NpeTFQdkNjUEhzcmlCRkVadmR4SzJtcG54MFVGeTh2NVZISlJ2VTNvbXdwc0d3V1h6OFREQkE2UXp6UFJpa3lSZGF3cjlWNWxPOV9WNXVNa1g3LUZhUVRCM3hyc3ZIX3VhM2IySGlXUG9Hbm9wQm4zWjF3ZjdBcmk0ZThSZENPRUd1eXY1RGZtOFA4eHQtV3B5YXQ0anBmbkc2S3FB?oc=5", "source_name": "GuruFocus", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals stock falls on trial data release", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQcGZ2V2hZSjR2VFMxWmhKRWp2YkRmc2J3SURpME9rdHEzemdaclU0VUtXZmMtUy1mZjl1VHF3cE9taEdsNy1xQTVLbjR6emQxcFNTWjFYUng1X255R0J6NV91N0hmNWQyZmxzTEVpREdBNmJzbDRuWXptM0JHQzZGeFpRNm94dlZFMmZIQjQ0dnRtbXNlelhzcXc1WTUxcU9MNEZSZ3FhTlhZVnpHUEl6Y1VxdGs3QS1CUEE?oc=5", "source_name": "Investing.com", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Teases Key ASCO Cancer Data, Late-Summer Obesity Readout", "summary": "", "url": "https://finance.yahoo.com/m/2c88be99-40bd-303b-be11-816d5d2159a7/corbus-pharmaceuticals-teases.html", "source_name": "MarketBeat", "published_at": "2026-05-22T07:04:54+00:00", "published_display": "22 May 2026 07:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/corbus-pharmaceuticals-announces-appointment-nishant-120000827.html", "source_name": "GlobeNewswire", "published_at": "2026-05-21T12:00:00+00:00", "published_display": "21 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Keeping An Eye On Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn Rate", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxNb1JQeHNlQ1dZNzN2ZDZhVXVSU0swZVRTVF9NS3lxeXU5Wk4tb3V5S3JocWhHemdNWU10SnA5dS1nUlBsV2ZrSXFMUWQ2amxFa01CWmw1c2V4QVZPS0V5MEZmSkxrYl9ZTHlFeVlqb2VPVEh6SzlORXowdFlYeHdJOTFMemkxMmJVV1IwV2UxbEFYZ21lZ2FVTmpSOXN3cXZhTTZuZW81QjJuYm9xSThWZzVPU0xxQWpvVG93NHBibWFWT3FVOTRnUkhpcTVqbWRGbTRpMHk2RV8ycXhGNlNNbVVDeUFXRjlLUl9tU3ZuUTllZEtDUC1kONIB_gFBVV95cUxQcjhtQkFOVHV5Y3cwTlBLNUlaRV9INnc2aGFxYXZjX0dVXzF0bkcyQlg4RFlwY3hWcHFFbFFVd3Zxa0w5TzdWMGtsckluR0x2Z3U0dWZxbnh4ZU1QZ2s3dWN3bU5UZTAteUU1aDJOemY4YVU1TDVyRlZCd2d2dmZnUlBlbFhrcU43LVdPTWVDZEUxY2szeGVRU3c4dkVoV3B5Vzdsc2lLQmtCZWdEWmR2cVNYWU9WdHh5RjF4SENMMVhVWU1xcVo4LUc5SWpWRDhnUFJzam1vblgzRHZSMXpTRjhEMlFCYVR1UnhDS0c0bkNqV09RYm9fZjBDOHJZUQ?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/corbus-pharmaceuticals-appoints-pharma-industry-120000727.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T12:00:00+00:00", "published_display": "14 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Oppenheimer Adjusts Price Target on Corbus Pharmaceuticals to $54 From $57, Maintains Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/news/oppenheimer-adjusts-price-target-corbus-130147922.html", "source_name": "MT Newswires", "published_at": "2026-05-13T13:01:47+00:00", "published_display": "13 May 2026 13:01", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/news/corbus-pharmaceuticals-participate-upcoming-investor-110000589.html", "source_name": "GlobeNewswire", "published_at": "2026-05-13T11:00:00+00:00", "published_display": "13 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Corbus to unpack 75-patient head and neck cancer data at June 1 ASCO panel", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNUzNzcVJiYW1XVmFQV0p5TW8xVldhVklSZ0o5a0R2QVVNaDZRSTJxSjZ1cUtvWWVWRnppN2Z1MG51YnVVTXBGWkw2TmhPNWtsS2VyNi1wLTZwVU5SVzBOY3BoenpncHdVOXBsVEx5OWx0a2c0LUtwWnMwRDdseDJBd21NdTFTNDlSODB2WVhHYklYdHVxZFFmaEZGdVpHLUVEekU3UFMxWl92VEZDMmF0b2xHbkdVeDFlTGRYcg?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Mizuho Sees Strong Risk-Reward in Corbus Pharmaceuticals Holdings, Inc. (CRBP) Near Cash Value", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOSWx3ek9qalJZU3F3V1Y3czBRRl8ydFd4ci1PMnpYclZtWUFwLVRmWUNBYUhIUC00dU9DRWllbzdqdnZ6TkhDMEJmTkR4cTR3Q0dEUkJJYU9BLTlhSWZFcDNkN3pVdGpTTEJaeTV5OGZSNXpLQ2p2UERqRmJzX2RvSDVRYTgwemFWa0lEZlRZWFRQbGhfZHdNQnEtUUxpVG9M?oc=5", "source_name": "Market source", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two cancer trials move ahead after FDA aligns on Corbus plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQbXEyYXYxTkppWFRRNEEwM2s3VHR5bTM5bnM4My1teDd2SFhlR2xaN3IzeXpQYXRYNm1Va0ZDNG52bHQ5WHF0QklsNFlPYkVlTkNpMmtFdnE3eVdwVXV1MDZZZDh0YnI1azE4TlZ0b1BmQ3dGb3F5RGV3eV9KTWc3bkhqRUZ3SHZsdks3UU5LN0ZhSkdMMnI4SU9zOVlhMC10Y3g3OWRaNnFYX21kNURDNDVSV1drdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "CORBUS PHARMACEUTICALS HLDGS ($CRBP) Releases Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPZDBzNDZ1MF9NYjRNRlhXRUU4WkRpWFNJZGNrYkx1d2NlUmlYWmhLckhEWlZsZC1PcTdiRzA4LUhtNXU1YkNETDJjSnh5WjZRYktiYmRvOTR5dHFqVUlDcVEtVlYyMERVVmlfcVdfRExWT091YkZCNkFYbzJQUXRKRDdpbnk0NzJJdDFBWEw4TllXY25XNVpydkYyeE9XYWthRTlJ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceu (CRBP) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9BQl96enl1aVZxTW51ZURaYWw1S2NtQ1diNW1ONExnbm12SWVDTXgxRjRzTjNjSVJJVVpWcUdRYTJRSERoWkt3UnNZNk84eV9PNC04?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:25:28+00:00", "published_display": "25 Apr 2025 00:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharma's Cancer Drug CRB-701 Advances: Key Clinical Data Coming at ASCO-GU - Patient Enrollment Exceeds Targets", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQbzhNcFFMN1U4eHBPaHBLSlFuZ2pYVFlnTS1WQmJHbF9YVnJWckFIWjdtSHRScWRYS3NrbWZMMnp5UTBEV3VrTFNXMFFOOUVvOXB5ekFxblNCQnR4TXdnbTRMTEZmRGZ2dUZVaUhNU3FuMkdLVVRrUUZQaVdpeWh4clBhZHdadHA1Y0VKczRpQ1VnR2E1Wk1sYURjQ0FNX0pacDlBZmJxN0dUUnJoZF8yR0xzQTByM3o2Rmc?oc=5", "source_name": "Stock Titan", "published_at": "2025-02-11T08:00:00+00:00", "published_display": "11 Feb 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Announces Release of CRB-701 Clinical Study Abstract Ahead of ASCO GU Symposium", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOYTJnXzBMOVgtTUVoUmszek85WmVDMEw1dXBZVlJuR0otV05WbnU0eG83MFVrbExWTGM0TGdocE5sQlljVjNXbzNtdk5wLThUV3A2NGMtTXpEZ3M4ekl6VzBld1JWQmhaMnBnVkZxcFlfSW9TbVNwMGlnODZ3TmlEcWdramJJVWN2dzNYeXRseUFNM1pjQkV0TC01M2tlbGt2ZlR6cmF3VHBhMDJ6UmVhUVRDRDdRc3BTYXUyWjlNeHlzNU5qd29zeDJ1Y1BpZGhi?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-02-11T08:00:00+00:00", "published_display": "11 Feb 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Reports Fourth Quarter 2022 and Year-End Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-wFBVV95cUxNdVlxYXNUQ3FYUVZDdVJMZmk1WVE0WDBzclhnbXBwTE1RT2k0RHJGMkdBeDFZaEhDZkFGdE9RV0ptVTJmVnJIRWdlX1EzWWt5VWxiMGRJM1BzUEdpenM1RzhLY1lWNUhJS2FEak5laV9wX2RDcEl3eFlGLV9FZndxdzh6V1prdnc2OXlkR1VBdlY5RDRwSmt2RTQzbDNKUmpGT2tsWWpucE53WEthc3B2dEpIbmRuNUt6ZThHZHhxZk1WS2RaS3FNd2NhWlhBc0txdVBQQ2pNaEg5eXk3Y1ZacDJnVVdvT1JucjZlTG1jbWp2aHBfcTdOTVYtWQ?oc=5", "source_name": "PR Newswire", "published_at": "2023-03-07T08:00:00+00:00", "published_display": "07 Mar 2023 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals expands oncology pipeline with the addition of a clinical stage Nectin-4 targeting Antibody Drug Conjugate (ADC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAJBVV95cUxOTXU3T3haVEFJbml3OVVBRi1semx3N01rYkdHVXl1R19peDJMY3d6YWQ3eFZybG5WTjUtLXVBVzBOVXRyRE1xTXFwdV9SQjdCR2tJS2t5QkdrUlhGa1JRQ1VPejdmUFAycTh3YlAyQWlVUUNwSjRvaGt5ZHN4cklBSURpbnlzOWRQZVZnMzVHazRHUFBjcVdfa3dNUVZuZnBQUG1oUGZ5ZjFqLVhrbVhtZkFyeUFfaEd5eVJoTjdDVldTMVNZUUxET0JiR2pEZ0h1bUk3M1V6LTJVU3hDX1c0YWJzVFNWNDZtc3dPX1VtcGc2QVpHa05wOUdlaUgxb055V2s2V0Y2a1pONC01bEpMcThJYWJfakg3?oc=5", "source_name": "PR Newswire", "published_at": "2023-02-13T08:00:00+00:00", "published_display": "13 Feb 2023 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals - CRBP - Stock Price & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE5tMmcwTXFFcUV0V1dsRERRNWp3bjFMbGVCdjVhZDZOalgyUmFZZmhZUTZYLTNUU2VEYTVBQXhQenltRUlWM1FwNTY3cUlMUnl4?oc=5", "source_name": "The Motley Fool", "published_at": "2021-09-13T22:15:35+00:00", "published_display": "13 Sep 2021 22:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "'We're ahead of the pack' in the cannabinoid drug space, says CEO of synthetic drugmaker Corbus", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNeE43LTJFSHdzTEI4ZUwta1hHMDFaMk15VFRaZ1hIZmJLa0x1MGhkaVhfRW9iTDBBWlgycTBYQUlPajRTU1pudWVqVGc0WVl0SXlHN09NUVJLN3pPWmw2MzVGMkFldzRMdkRNM0FuZjZiS3czbVlyUlI1cG5RYWdVckQtamNyRWhCZnc1WWhYajRvdnRFOVZMN1padFAtZDZQaENB0gGoAUFVX3lxTE9VVmU2RlpvOVl5eDQ3WlFNNmktT2JBVUp6djItQlN5VjUwUzVRYm9kWWVPMUxqc0k1MTVlaVFSTVlGbGVxUFFncFJQcFRhdG5saU4wVm9YWkk3eTgyZEl1emlXcXpURnY3OUlhTC1hZkVVNHg1bDVSRFl5WURkNjJiQXpJREprSUhoRC1nb0N3bVNCRWx6SlJvS2d5SG02SXdRMEpXdDFQeg?oc=5", "source_name": "CNBC", "published_at": "2018-09-20T07:00:00+00:00", "published_display": "20 Sep 2018 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Corbus Pharmaceuticals Holdings Inc. stock rises Tuesday, still underperforms market", "summary": "Corbus Pharmaceuticals Holdings Inc. (CRBP) saw its stock rise by 1.01% on Tuesday, closing at $8.98. Despite this increase, the stock underperformed the broader market, as both the NASDAQ Composite and Dow Jones Industrial Average also climbed. The company's shares remain signif", "url": "https://www.marketwatch.com/data-news/corbus-pharmaceuticals-holdings-inc-stock-rises-tuesday-still-underperforms-market-f4e4aba9-5ba1e4ebaba0", "source_name": "MarketWatch", "published_at": "2026-07-21T17:19:00", "published_display": "21 Jul 2026 17:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day", "summary": "Corbus Pharmaceuticals Holdings Inc. (CRBP) saw its stock rise by 2.39% to $9.01 on Friday, despite a generally poor trading session for the broader market where both the NASDAQ Composite and Dow Jones Industrial Average declined. This increase broke a four-day losing streak for ", "url": "https://www.marketwatch.com/data-news/corbus-pharmaceuticals-holdings-inc-stock-outperforms-competitors-on-strong-trading-day-36aa5d5f-4b50e581e36d?mod=mw_quote_news", "source_name": "MarketWatch", "published_at": "2026-07-17T17:20:00", "published_display": "17 Jul 2026 17:20", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day", "summary": "Corbus Pharmaceuticals Holdings Inc. (CRBP) saw its stock price decline by 2.33% to $8.80, marking its fourth consecutive day of losses. This occurred during a general market downturn, with both the NASDAQ Composite and Dow Jones Industrial Average also falling. Despite the daily", "url": "https://www.marketwatch.com/data-news/corbus-pharmaceuticals-holdings-inc-stock-outperforms-competitors-despite-losses-on-the-day-41ad6dc9-a0d0144f05cd?mod=goog_fin_scmw", "source_name": "MarketWatch", "published_at": "2026-07-16T17:19:00", "published_display": "16 Jul 2026 17:19", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors", "summary": "Shares of Corbus Pharmaceuticals Holdings Inc. (CRBP) fell 6.61% to $9.04 on Monday, breaking a four-day winning streak. This underperformance occurred during an overall poor trading session, with the NASDAQ Composite Index falling 1.55% and the Dow Jones Industrial Average decli", "url": "https://www.marketwatch.com/data-news/corbus-pharmaceuticals-holdings-inc-stock-underperforms-monday-when-compared-to-competitors-31c79946-c684017a7ce7?mod=mw_quote_news", "source_name": "MarketWatch", "published_at": "2026-07-13T17:21:00", "published_display": "13 Jul 2026 17:21", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Corbus Pharmaceuticals Holdings, Inc. \u2013 NASDAQ:CRBP", "summary": "This article provides financial information for Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) from TradingView, specifically focusing on its enterprise value to EBIT forward. The content appears to be a financial data page rather than a traditional article, offering variou", "url": "https://www.tradingview.com/symbols/NASDAQ-CRBP/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T12:39:18", "published_display": "12 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer", "summary": "Corbus Pharmaceuticals Holdings, Inc. has announced the appointment of Leonardo Viana Nicacio, M.D., as its new Chief Medical Officer. Dr. Nicacio brings extensive experience in solid tumor drug development, particularly with antibody-drug conjugates (ADCs) and HPV-driven oncolog", "url": "https://www.theglobeandmail.com/investing/markets/stocks/CRBP-Q/pressreleases/36762811/corbus-pharmaceuticals-appoints-leonardo-viana-nicacio-m-d-as-chief-medical-officer/", "source_name": "The Globe and Mail", "published_at": "2026-07-11T04:11:21", "published_display": "11 Jul 2026 04:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Holdings Inc. stock rises Thursday, still underperforms market", "summary": "Corbus Pharmaceuticals Holdings Inc. (CRBP) stock increased by 1.15% on Thursday, closing at $9.66", "url": "https://www.marketwatch.com/data-news/corbus-pharmaceuticals-holdings-inc-stock-rises-thursday-still-underperforms-market-c8094119-b093795a5eb2", "source_name": "MarketWatch", "published_at": "2026-07-09T17:18:00", "published_display": "09 Jul 2026 17:18", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains", "summary": "Corbus Pharmaceuticals Holdings Inc. (CRBP) saw its stock increase by 1.81% on Wednesday, closing at $9.55, despite the broader market showing mixed results. The NASDAQ Composite Index rose while the Dow Jones Industrial Average fell. This marks the second consecutive day of gain", "url": "https://www.marketwatch.com/data-news/corbus-pharmaceuticals-holdings-inc-stock-underperforms-wednesday-when-compared-to-competitors-despite-daily-gains-bf0e718f-cdd3a285e37e", "source_name": "MarketWatch", "published_at": "2026-07-08T17:17:00", "published_display": "08 Jul 2026 17:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio as Chief Medical Officer", "summary": "Corbus Pharmaceuticals has appointed Leonardo Viana Nicacio, M.D., as Chief Medical Officer, strengthening its oncology drug development team. This appointment comes as Corbus prepares to advance multiple oncology and obesity programs, including the registrational TEMPO-1 study f", "url": "https://www.citybiz.co/article/870216/corbus-pharmaceuticals-appoints-leonardo-viana-nicacio-as-chief-medical-officer/", "source_name": "citybiz", "published_at": "2026-07-06T17:40:32", "published_display": "06 Jul 2026 17:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Holdings, Inc. Announces Appointment of Leonardo Viana Nicacio as Chief Medical Officer", "summary": "Corbus Pharmaceuticals Holdings, Inc. has announced the appointment of Leonardo Viana Nicacio, M.D., as its new Chief Medical Officer. Dr. Nicacio brings over 20 years of experience in the pharmaceutical industry, having previously served as Chief Medical Officer at Protara Thera", "url": "https://www.marketscreener.com/news/corbus-pharmaceuticals-holdings-inc-announces-appointment-of-leonardo-viana-nicacio-as-chief-medic-ce7f5edbdb8cf02d", "source_name": "www.marketscreener.com", "published_at": "2026-07-06T15:40:32", "published_display": "06 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer", "summary": "Corbus Pharmaceuticals has announced the appointment of Leonardo Viana Nicacio, M.D., as its new Chief Medical Officer, effective immediately. Dr. Nicacio brings extensive experience in drug development across various therapeutic areas, including oncology and rare diseases, which", "url": "https://www.moomoo.com/news/post/72522140/press-release-corbus-pharmaceuticals-appoints-leonardo-viana-nicacio-md-as", "source_name": "Moomoo", "published_at": "2026-07-06T12:42:07", "published_display": "06 Jul 2026 12:42", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals names Leonardo Nicacio as CMO By Investing.com", "summary": "Corbus Pharmaceuticals Holdings, Inc. announced the appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer, bringing over 20 years of pharmaceutical industry experience to the company. Dr. Nicacio previously held significant roles at Protara Therapeutics, Seagen, A", "url": "https://ca.investing.com/news/stock-market-news/corbus-pharmaceuticals-names-leonardo-nicacio-as-cmo-93CH-4720854", "source_name": "Investing.com Canada", "published_at": "2026-07-06T12:25:35", "published_display": "06 Jul 2026 12:25", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals (NASDAQ: CRBP) hires new CMO and details CRB-701, CRB-913 timelines", "summary": "Corbus Pharmaceuticals has appointed Leonardo Viana Nicacio, M.D., as its new Chief Medical Officer, effective August 3, 2026, with a compensation package including a $545,000 base salary and $2.1 million in equity awards. The company also outlined key clinical development milest", "url": "https://www.stocktitan.net/sec-filings/CRBP/8-k-corbus-pharmaceuticals-holdings-inc-reports-material-event-ccc2dd374f59.html", "source_name": "Stock Titan", "published_at": "2026-07-06T12:16:35", "published_display": "06 Jul 2026 12:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus adds new medical chief ahead of CRB-701 cancer study", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQdzZIblRkYVliU0F5MFdZVEhiRGlQN0R5aWhicVFJVXZuVnVqaW5fbF9WcFd3b0xha2k5U3h4eTBEdG50bXQxSjBTYjBqdDdxOEZCUkZBM0JBbFNFckhFX1F3cElYZzVwZ2lXRGtpbUVJTFlIcmRnRWtIX2g3S19fMDQ3TEJ3cGl0OFdqYk9heEMwNmN0N1FfOEFCMEt6QTZvWEd5Ym9tUGVWVzNzeHQ3dU5GRGw1d3lrNkhjallkQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals outlines its immuno-oncology strategy as a clinical-stage biotech", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPQlBqdTRwZExCamZWQ0NJNVhXVnN2NWs1dEVMd2ZvUTdFOVQyWTlrN1BGSFhsb0szUGVpRTB4VkVGV1I3Y1dIU3RCSVhtaVFHRTllLWZGX093MV9kQks5b1h6SGhYcTB5UF9EVnlGRjU5YTByU2t0aDRVRno5Z2ZoLWtXSDVtVW40UlhiUVFiX3dzbU0tM0pORmo4TjJuQkhqaXVWWWlaaDNDN2ZGSWJiVDkxWWpRcXNVTjZfQlEyWHJxZw?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T13:59:45+00:00", "published_display": "03 Jul 2026 13:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors despite daily gains", "summary": "Corbus Pharmaceuticals Holdings Inc. (CRBP) stock rose 1.98% on Thursday to $9.25, amidst a mixed trading session where the Dow Jones Industrial Average gained 1.14% and the NASDAQ Composite Index fell 0.80%. Despite the daily gains, the stock underperformed compared to some comp", "url": "https://www.marketwatch.com/data-news/corbus-pharmaceuticals-holdings-inc-stock-underperforms-thursday-when-compared-to-competitors-despite-daily-gains-5fdb9891-50af8718823a?mod=mw_quote_news", "source_name": "MarketWatch", "published_at": "2026-07-02T16:17:00", "published_display": "02 Jul 2026 16:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors", "summary": "Shares of Corbus Pharmaceuticals Holdings Inc. (CRBP) fell 3.30% on Wednesday, closing at $9.07. This underperformance occurred during a generally negative trading session, with both the NASDAQ Composite Index and the Dow Jones Industrial Average also declining. The stock's drop ", "url": "https://www.marketwatch.com/data-news/corbus-pharmaceuticals-holdings-inc-stock-underperforms-wednesday-when-compared-to-competitors-c6d2c92b-dbdc105215da?mod=goog_fin_scmw", "source_name": "MarketWatch", "published_at": "2026-07-01T17:19:00", "published_display": "01 Jul 2026 17:19", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(CRBP) Risk Channels and Responsive Allocation", "summary": "This article provides a detailed analysis of Corbus Pharmaceuticals Holdings Inc. (CRBP), highlighting near and mid-term strong sentiment but a weak long-term outlook. It outlines several AI-generated trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging\u2014with s", "url": "https://news.stocktradersdaily.com/news_release/38/CRBP_Risk_Channels_and_Responsive_Allocation_063026042002_1782850802.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-30T16:20:00", "published_display": "30 Jun 2026 16:20", "sentiment": "positive", "sentiment_pct": 63, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell 2000 Value Benchmark", "summary": "Corbus Pharmaceuticals Holdings, Inc. (NasdaqCM: CRBP) has been added to the Russell 2000 Value Benchmark, effective June 29, 2026. This news follows a previous announcement of its inclusion in the Russell 3000E Index. The company is focused on oncology and obesity, with a pipeli", "url": "https://www.marketscreener.com/news/corbus-pharmaceuticals-holdings-inc-nasdaqcm-crbp-added-to-russell-2000-value-benchmark-ce7f5fdfd888f024", "source_name": "marketscreener.com", "published_at": "2026-06-29T14:41:46", "published_display": "29 Jun 2026 14:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Corbus Pharmaceuticals Holdings, Inc. \u2013 BOATS:CRBP", "summary": "This article provides the enterprise value to EBIT forward for Corbus Pharmaceuticals Holdings, Inc. (CRBP) within the Blue Ocean Alternative Trade System (BOATS) on TradingView. It indicates that the market was closed at the time of viewing and presents financial data provided b", "url": "https://www.tradingview.com/symbols/BOATS-CRBP/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T10:39:10", "published_display": "26 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRBP Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast for Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock, including current price, historical performance, analyst price targets, and key financial data. It highlights that analysts have a max estimated price target of $52.00 and a min of $17.00. The", "url": "https://www.tradingview.com/symbols/NASDAQ-CRBP/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T06:10:35", "published_display": "26 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Corbus Pharmaceuticals Holdings, Inc. \u2013 NASDAQ:CRBP", "summary": "This article provides financial information for Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), specifically focusing on its enterprise value to revenue forward. It appears to be a financial data point from TradingView, a platform offering market data and analysis tools.", "url": "https://www.tradingview.com/symbols/NASDAQ-CRBP/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T23:10:35", "published_display": "25 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer Adjusts PT on Corbus Pharmaceuticals to $52 From $54, Maintains Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/oppenheimer-adjusts-pt-corbus-pharmaceuticals-123131238.html", "source_name": "MT Newswires", "published_at": "2026-06-17T12:31:31+00:00", "published_display": "17 Jun 2026 12:31", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near", "summary": "", "url": "https://finance.yahoo.com/m/16c5a21f-3ef1-3c53-827b-64fa4b9b6b57/corbus-pharmaceuticals-teases.html", "source_name": "MarketBeat", "published_at": "2026-06-09T09:02:11+00:00", "published_display": "09 Jun 2026 09:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Spends US$101k Buying More Shares In Corbus Pharmaceuticals Holdings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxNSENWcDdod0xuWHVnSFdGZ1JIamxoOGdyWm5McDFMWUNFX2xfcVJtbTZ3cEVVbDZianhRUXBPUG1NQkRqRl9RekpTaTlMZXZ0VFpBZUdteGdiTnliSlFEMXVFS1JZRTFNSTNPWmUzM0NMV1JuTDVvZy1QTEhfQnpob25oSG1CTE0wejVISjE2YndnWGthcW5TMGxGUlBDX0pmRk43QVFWNmNCbGdfcHV4VWlLX1B4c19HU3VSM2JLcWJ2cnJabjFneFBjQXczQm4xTG5YNVJOM3JxbmluLVljT29tZ1g0cjN5Vl9PX0Y3aEVyUUwzT0ZmQdIB_gFBVV95cUxQUEtaWGlGOVhFbllLd0pwYmVjVThlWEZfNGdjUkxhQTFFUlQ0WXZjY3JtejBPMzlPb0ZnampScm5NUmU3d2dCOE5EckZBcFhEQ2p2NXVWR3Zta3pMUGNNNXFlU2hINEpIVElmdUQ2aTY1d2J1eEM4X1JCN2FxRHhzWFZDOTB3aW9qczNNQnRBQk40bjBoUGp4cjV3Z080TS1RcDdTWFJERHhmLWIwZjhsNkhheVNHalVRT2FuLXVNdnlYUzg1LVdkMjhpd3NnTWpodXFJR0NrVGsyVUpuakpSa09ic2N5dk9RNG5ETXFUSnZNVGtYWnE1bHBjQ0t5dw?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus (CRBP) Chief Business Officer buys 13,500 shares in open market", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNaThmTk80V3kyTkZTUlZaeEFmMWJzMmlLQ3RFTDM4RnhWZmhNdFVETmtub2JFdndyOUllRk9udXFtUmxiNDh1enZDbG1hXzl6LVloWjBvSGdteWJTZDZsSFhZbjJRMzkxLXg0Qm1fUFNZSy13OWxHaURuN2VzTUpHbzM0TUhrTjV5ZHBTN2FaV1BoY3BhXzFCd0JQd1Exc1hfdWJ2bDByWW05U2VWR1NvdlJrSE1jUnRBeFc5OUR0dzZIX0FKc3p1Mg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study", "summary": "", "url": "https://finance.yahoo.com/m/8bb524be-8e00-344d-8d6f-f440cf9360ce/corbus-pharmaceuticals.html", "source_name": "MarketBeat", "published_at": "2026-06-01T14:04:00+00:00", "published_display": "01 Jun 2026 14:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock Price Today: $9.01", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE1DR2VsTzM3bzJhRWNyMXpzaHB5d044eWRCNi1QNDhOSEZUR1N0OGJ3WkhBNDF0THUxTFpWV1NDQlVRaHJhTmVXVTRUTUZzQ01qN0hoWUZ1dw?oc=5", "source_name": "Gotrade", "published_at": "2026-05-29T05:48:29+00:00", "published_display": "29 May 2026 05:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals (CRBP) Is Down 19.6% After FDA Aligns On CRB-701 Registrational Strategy - Has The Bull Case Changed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxNNTNyUTdyZ2Z5REhMZmpJaW1FSzEyOUlsMHM5VGdqQ3IydTRid21FSlhRbmpXYS1QNWdwX3lyT050MGFieWU1ZFl1cUVPUWZEOC01c3R1VlpWVFd2MVYtNy1IaU1nckFHNHFhWEhsVzdtTkZsMS1CazFtbE9PV0JIMk0yM2lDNVNUWTZucjMzZXdSczZRSEo5cGd4dThlbThHcDdidDZjdDBSUXNHTVByNy1LS1BDVllSdVN1SlRyeXRnTG9PcVpFVHhSNmtrVTRSYk4yNktfakY4bjRKTDZMRTFieDdhc0dQSy1PdXhUV1BWNWxOemI40gH8AUFVX3lxTE9mRzJKZTU2X1daNjZsYzkwbUpIc2JRTXRIdElLV1BVRlJaSDVDNmNFSDNoX002MjdicXlLbmdpZTJPR3lzVEU0TGRsSTZ2aFo2OEVVSFo5a2tLODV4aGJNODQ3Yk01Z1JndkFQRHlNLVcwOVB5bk1kUE1Qc2h0bVhXWG9sSUdrWFFEa0lmN3pDTHh1czBxbkZFUE5ZTWM3eGRIcHJoTTMtWU9TNWNpdXZFRE5mcHhTdFo0RkJqem9pMEttdnhXZUplQ1NLTXJ4eU5raGRvclA3UTcxdTVjUnhERlNsTkJRaVIxQVotajNBYnpzeWRsc2paZzFmNg?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals: I'd Preach Caution After Selloff On Latest Data Drop (NASDAQ:CRBP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPYlRqaWRXc0VPblV4NjNxOXdONHhhMGp3eWRLUWxaWGl1OEV1TEVVdGg1VWNralNjeVJBbm9jdlJFYWU0SVJkSU1VU0wxbnkwS2xsTG5nQmxsZVFqR3BpOTJBejZKOFJhaGJYaGd4Qms5ck1pV1FYdjgxaEJTb3pYRHdkWGltZUpnZzUxdmVkcmp6WmdYUDM2UXRlTFBuYkpfZEs0Z1BNNk5TUlZOQ2l3d0V3ZURaQQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/corbus-pharmaceuticals-reports-updated-crb-110000390.html", "source_name": "GlobeNewswire", "published_at": "2026-05-26T11:00:00+00:00", "published_display": "26 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Stock (CRBP) Opinions on Updated CRB-701 Cancer Data Release", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPSE1VMS1uV1NnZldoUG1VbXRRaHpCQ0F3c0dkWF9UTnRkem40LUhoR2lTRFJqV2J3bFZCQ1hISFhCQ016OVBKTktSZE83NVBrMzB6VlNnOXJKbHNiQk0zbDlrZG84NHJGTl9DcmhSemNVa0NKSDE3X0xaMl9ta3BFZEZBQ3FmTHJzWkdXLS1vVXB5SG4tLWxPQ2VaREQ2QU0wSUJaakc1MFFqOERZb2RtaGV2N19XS0VweFpucA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharma (CRBP) Faces Premarket Decline Following Phase 1/2 Trial Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPU28zVTcwN0FrRzZobFpjWUp5ZG01d192R1FSVTB3eEE3UXFxc3FTNUw0SnVMb2Q1a1NpeTFQdkNjUEhzcmlCRkVadmR4SzJtcG54MFVGeTh2NVZISlJ2VTNvbXdwc0d3V1h6OFREQkE2UXp6UFJpa3lSZGF3cjlWNWxPOV9WNXVNa1g3LUZhUVRCM3hyc3ZIX3VhM2IySGlXUG9Hbm9wQm4zWjF3ZjdBcmk0ZThSZENPRUd1eXY1RGZtOFA4eHQtV3B5YXQ0anBmbkc2S3FB?oc=5", "source_name": "GuruFocus", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals stock falls on trial data release", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQcGZ2V2hZSjR2VFMxWmhKRWp2YkRmc2J3SURpME9rdHEzemdaclU0VUtXZmMtUy1mZjl1VHF3cE9taEdsNy1xQTVLbjR6emQxcFNTWjFYUng1X255R0J6NV91N0hmNWQyZmxzTEVpREdBNmJzbDRuWXptM0JHQzZGeFpRNm94dlZFMmZIQjQ0dnRtbXNlelhzcXc1WTUxcU9MNEZSZ3FhTlhZVnpHUEl6Y1VxdGs3QS1CUEE?oc=5", "source_name": "Investing.com", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Teases Key ASCO Cancer Data, Late-Summer Obesity Readout", "summary": "", "url": "https://finance.yahoo.com/m/2c88be99-40bd-303b-be11-816d5d2159a7/corbus-pharmaceuticals-teases.html", "source_name": "MarketBeat", "published_at": "2026-05-22T07:04:54+00:00", "published_display": "22 May 2026 07:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/corbus-pharmaceuticals-announces-appointment-nishant-120000827.html", "source_name": "GlobeNewswire", "published_at": "2026-05-21T12:00:00+00:00", "published_display": "21 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Keeping An Eye On Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn Rate", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxNb1JQeHNlQ1dZNzN2ZDZhVXVSU0swZVRTVF9NS3lxeXU5Wk4tb3V5S3JocWhHemdNWU10SnA5dS1nUlBsV2ZrSXFMUWQ2amxFa01CWmw1c2V4QVZPS0V5MEZmSkxrYl9ZTHlFeVlqb2VPVEh6SzlORXowdFlYeHdJOTFMemkxMmJVV1IwV2UxbEFYZ21lZ2FVTmpSOXN3cXZhTTZuZW81QjJuYm9xSThWZzVPU0xxQWpvVG93NHBibWFWT3FVOTRnUkhpcTVqbWRGbTRpMHk2RV8ycXhGNlNNbVVDeUFXRjlLUl9tU3ZuUTllZEtDUC1kONIB_gFBVV95cUxQcjhtQkFOVHV5Y3cwTlBLNUlaRV9INnc2aGFxYXZjX0dVXzF0bkcyQlg4RFlwY3hWcHFFbFFVd3Zxa0w5TzdWMGtsckluR0x2Z3U0dWZxbnh4ZU1QZ2s3dWN3bU5UZTAteUU1aDJOemY4YVU1TDVyRlZCd2d2dmZnUlBlbFhrcU43LVdPTWVDZEUxY2szeGVRU3c4dkVoV3B5Vzdsc2lLQmtCZWdEWmR2cVNYWU9WdHh5RjF4SENMMVhVWU1xcVo4LUc5SWpWRDhnUFJzam1vblgzRHZSMXpTRjhEMlFCYVR1UnhDS0c0bkNqV09RYm9fZjBDOHJZUQ?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/corbus-pharmaceuticals-appoints-pharma-industry-120000727.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T12:00:00+00:00", "published_display": "14 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer Adjusts Price Target on Corbus Pharmaceuticals to $54 From $57, Maintains Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/news/oppenheimer-adjusts-price-target-corbus-130147922.html", "source_name": "MT Newswires", "published_at": "2026-05-13T13:01:47+00:00", "published_display": "13 May 2026 13:01", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/news/corbus-pharmaceuticals-participate-upcoming-investor-110000589.html", "source_name": "GlobeNewswire", "published_at": "2026-05-13T11:00:00+00:00", "published_display": "13 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus to unpack 75-patient head and neck cancer data at June 1 ASCO panel", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNUzNzcVJiYW1XVmFQV0p5TW8xVldhVklSZ0o5a0R2QVVNaDZRSTJxSjZ1cUtvWWVWRnppN2Z1MG51YnVVTXBGWkw2TmhPNWtsS2VyNi1wLTZwVU5SVzBOY3BoenpncHdVOXBsVEx5OWx0a2c0LUtwWnMwRDdseDJBd21NdTFTNDlSODB2WVhHYklYdHVxZFFmaEZGdVpHLUVEekU3UFMxWl92VEZDMmF0b2xHbkdVeDFlTGRYcg?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Sees Strong Risk-Reward in Corbus Pharmaceuticals Holdings, Inc. (CRBP) Near Cash Value", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOSWx3ek9qalJZU3F3V1Y3czBRRl8ydFd4ci1PMnpYclZtWUFwLVRmWUNBYUhIUC00dU9DRWllbzdqdnZ6TkhDMEJmTkR4cTR3Q0dEUkJJYU9BLTlhSWZFcDNkN3pVdGpTTEJaeTV5OGZSNXpLQ2p2UERqRmJzX2RvSDVRYTgwemFWa0lEZlRZWFRQbGhfZHdNQnEtUUxpVG9M?oc=5", "source_name": "Market source", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two cancer trials move ahead after FDA aligns on Corbus plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQbXEyYXYxTkppWFRRNEEwM2s3VHR5bTM5bnM4My1teDd2SFhlR2xaN3IzeXpQYXRYNm1Va0ZDNG52bHQ5WHF0QklsNFlPYkVlTkNpMmtFdnE3eVdwVXV1MDZZZDh0YnI1azE4TlZ0b1BmQ3dGb3F5RGV3eV9KTWc3bkhqRUZ3SHZsdks3UU5LN0ZhSkdMMnI4SU9zOVlhMC10Y3g3OWRaNnFYX21kNURDNDVSV1drdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CORBUS PHARMACEUTICALS HLDGS ($CRBP) Releases Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPZDBzNDZ1MF9NYjRNRlhXRUU4WkRpWFNJZGNrYkx1d2NlUmlYWmhLckhEWlZsZC1PcTdiRzA4LUhtNXU1YkNETDJjSnh5WjZRYktiYmRvOTR5dHFqVUlDcVEtVlYyMERVVmlfcVdfRExWT091YkZCNkFYbzJQUXRKRDdpbnk0NzJJdDFBWEw4TllXY25XNVpydkYyeE9XYWthRTlJ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceu (CRBP) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9BQl96enl1aVZxTW51ZURaYWw1S2NtQ1diNW1ONExnbm12SWVDTXgxRjRzTjNjSVJJVVpWcUdRYTJRSERoWkt3UnNZNk84eV9PNC04?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:25:28+00:00", "published_display": "25 Apr 2025 00:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharma's Cancer Drug CRB-701 Advances: Key Clinical Data Coming at ASCO-GU - Patient Enrollment Exceeds Targets", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQbzhNcFFMN1U4eHBPaHBLSlFuZ2pYVFlnTS1WQmJHbF9YVnJWckFIWjdtSHRScWRYS3NrbWZMMnp5UTBEV3VrTFNXMFFOOUVvOXB5ekFxblNCQnR4TXdnbTRMTEZmRGZ2dUZVaUhNU3FuMkdLVVRrUUZQaVdpeWh4clBhZHdadHA1Y0VKczRpQ1VnR2E1Wk1sYURjQ0FNX0pacDlBZmJxN0dUUnJoZF8yR0xzQTByM3o2Rmc?oc=5", "source_name": "Stock Titan", "published_at": "2025-02-11T08:00:00+00:00", "published_display": "11 Feb 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Announces Release of CRB-701 Clinical Study Abstract Ahead of ASCO GU Symposium", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOYTJnXzBMOVgtTUVoUmszek85WmVDMEw1dXBZVlJuR0otV05WbnU0eG83MFVrbExWTGM0TGdocE5sQlljVjNXbzNtdk5wLThUV3A2NGMtTXpEZ3M4ekl6VzBld1JWQmhaMnBnVkZxcFlfSW9TbVNwMGlnODZ3TmlEcWdramJJVWN2dzNYeXRseUFNM1pjQkV0TC01M2tlbGt2ZlR6cmF3VHBhMDJ6UmVhUVRDRDdRc3BTYXUyWjlNeHlzNU5qd29zeDJ1Y1BpZGhi?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-02-11T08:00:00+00:00", "published_display": "11 Feb 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals Reports Fourth Quarter 2022 and Year-End Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-wFBVV95cUxNdVlxYXNUQ3FYUVZDdVJMZmk1WVE0WDBzclhnbXBwTE1RT2k0RHJGMkdBeDFZaEhDZkFGdE9RV0ptVTJmVnJIRWdlX1EzWWt5VWxiMGRJM1BzUEdpenM1RzhLY1lWNUhJS2FEak5laV9wX2RDcEl3eFlGLV9FZndxdzh6V1prdnc2OXlkR1VBdlY5RDRwSmt2RTQzbDNKUmpGT2tsWWpucE53WEthc3B2dEpIbmRuNUt6ZThHZHhxZk1WS2RaS3FNd2NhWlhBc0txdVBQQ2pNaEg5eXk3Y1ZacDJnVVdvT1JucjZlTG1jbWp2aHBfcTdOTVYtWQ?oc=5", "source_name": "PR Newswire", "published_at": "2023-03-07T08:00:00+00:00", "published_display": "07 Mar 2023 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals expands oncology pipeline with the addition of a clinical stage Nectin-4 targeting Antibody Drug Conjugate (ADC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAJBVV95cUxOTXU3T3haVEFJbml3OVVBRi1semx3N01rYkdHVXl1R19peDJMY3d6YWQ3eFZybG5WTjUtLXVBVzBOVXRyRE1xTXFwdV9SQjdCR2tJS2t5QkdrUlhGa1JRQ1VPejdmUFAycTh3YlAyQWlVUUNwSjRvaGt5ZHN4cklBSURpbnlzOWRQZVZnMzVHazRHUFBjcVdfa3dNUVZuZnBQUG1oUGZ5ZjFqLVhrbVhtZkFyeUFfaEd5eVJoTjdDVldTMVNZUUxET0JiR2pEZ0h1bUk3M1V6LTJVU3hDX1c0YWJzVFNWNDZtc3dPX1VtcGc2QVpHa05wOUdlaUgxb055V2s2V0Y2a1pONC01bEpMcThJYWJfakg3?oc=5", "source_name": "PR Newswire", "published_at": "2023-02-13T08:00:00+00:00", "published_display": "13 Feb 2023 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corbus Pharmaceuticals - CRBP - Stock Price & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE5tMmcwTXFFcUV0V1dsRERRNWp3bjFMbGVCdjVhZDZOalgyUmFZZmhZUTZYLTNUU2VEYTVBQXhQenltRUlWM1FwNTY3cUlMUnl4?oc=5", "source_name": "The Motley Fool", "published_at": "2021-09-13T22:15:35+00:00", "published_display": "13 Sep 2021 22:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "'We're ahead of the pack' in the cannabinoid drug space, says CEO of synthetic drugmaker Corbus", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNeE43LTJFSHdzTEI4ZUwta1hHMDFaMk15VFRaZ1hIZmJLa0x1MGhkaVhfRW9iTDBBWlgycTBYQUlPajRTU1pudWVqVGc0WVl0SXlHN09NUVJLN3pPWmw2MzVGMkFldzRMdkRNM0FuZjZiS3czbVlyUlI1cG5RYWdVckQtamNyRWhCZnc1WWhYajRvdnRFOVZMN1padFAtZDZQaENB0gGoAUFVX3lxTE9VVmU2RlpvOVl5eDQ3WlFNNmktT2JBVUp6djItQlN5VjUwUzVRYm9kWWVPMUxqc0k1MTVlaVFSTVlGbGVxUFFncFJQcFRhdG5saU4wVm9YWkk3eTgyZEl1emlXcXpURnY3OUlhTC1hZkVVNHg1bDVSRFl5WURkNjJiQXpJREprSUhoRC1nb0N3bVNCRWx6SlJvS2d5SG02SXdRMEpXdDFQeg?oc=5", "source_name": "CNBC", "published_at": "2018-09-20T07:00:00+00:00", "published_display": "20 Sep 2018 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 99, "total_relevant": 61, "sentiment_summary": {"positive": 15, "negative": 6, "neutral": 40, "score": 52, "total": 61, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 86, "events": [{"event": "general", "label": "Market update", "weight": 26.25, "count": 42}, {"event": "earnings", "label": "Earnings", "weight": 6.26, "count": 13}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 15, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 9.01, "latest_week": "2026-07-17", "one_week_move": -6.9, "four_week_move": 9.1, "twelve_week_move": -10.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.289476, "market_dynamics_buy_signal": false, "relative_strength": -19.308956, "fair_value_gap": -47.2, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 49.9159, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-6.9% over one week, +9.1% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "MarketWatch", "count": 8}, {"label": "Market source", "count": 7}, {"label": "Stock Titan", "count": 7}, {"label": "TradingView", "count": 5}, {"label": "simplywall.st", "count": 5}, {"label": "GlobeNewswire", "count": 4}, {"label": "MarketBeat", "count": 3}, {"label": "Quiver Quantitative", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 52}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 42}, {"label": "Earnings", "count": 13}, {"label": "Analyst action", "count": 3}, {"label": "Balance sheet", "count": 2}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "86/100 classification confidence."}, {"label": "Company focus", "value": "52", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "10", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-6.9% over one week, +9.1% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Corbus Pharmaceuticals Holdings Inc. stock rises Tuesday, still underperforms market"}], "updated_at": "2026-07-22T06:08:54.895808+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}